Genmab CEO on legal fight with Janssen: Standing up straight and fighting for what's morally and ethically right

The trial between collaborative partners Genmab and Janssen is moving along, but according to Jan van de Winkel it's too early to conclude when a verdict will be made.

Photo: Mik Eskestad/ERH

Genmab and its CEO Jan van de Winkel will fight to the last breath in in its current dispute with US partner Janssen. At least, that is the impression you get from speaking to the Dutch bussinessman.

"Sometimes in life you just need to stand up straight and fight for what you believe is morally and ethically right. This is what we are doing here. We are a very ethical company, and I believe that we have the right to defend ourselves," says van de Winkel.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs